{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:13Z","timestamp":1763017993324,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11033-019-04816-5","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T10:03:19Z","timestamp":1556186599000},"page":"3747-3754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-5431","authenticated-orcid":false,"given":"Irina Cezara","family":"Vacarean-Trandafir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliu Cristian","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana Mihaiela","family":"Dragos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Smaranda","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia Andrea","family":"Titieanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dumitru","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"issue":"6105","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/325635a0","volume":"325","author":"LC Chan","year":"1987","unstructured":"Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powle R, Lawler SD, Groffen J, Foulkes JG, Greaves MF, Wiedemann LM et al (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia. Nature 325(6105):635","journal-title":"Nature"},{"issue":"5405","key":"4816_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290","journal-title":"Nature"},{"issue":"3","key":"4816_CR3","first-page":"196","volume":"5","author":"LM Secker-Walker","year":"1991","unstructured":"Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV (1991) Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 5(3):196\u2013199","journal-title":"Leukemia"},{"issue":"17","key":"4816_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340(17):1330\u20131340","journal-title":"N Engl J Med"},{"issue":"3","key":"4816_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3):172","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4816_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809\u20131820","journal-title":"Blood"},{"issue":"10","key":"4816_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB et al (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767","journal-title":"Leukemia"},{"issue":"1","key":"4816_CR8","first-page":"231","volume":"2011","author":"AK Fielding","year":"2011","unstructured":"Fielding AK (2011) Current treatment of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. ASH Education Program Book 2011(1):231\u2013237","journal-title":"ASH Education Program Book"},{"issue":"24","key":"4816_CR9","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M et al (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711\u20133719","journal-title":"Blood"},{"key":"4816_CR10","first-page":"93","volume":"125","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 125:93\u2013106","journal-title":"Methods Mol Med"},{"issue":"11","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, La Ros\u00e9e P, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11):4611\u20134614","journal-title":"Blood"},{"issue":"1","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","volume":"11","author":"D Jones","year":"2009","unstructured":"Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K et al (2009) Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 11(1):4\u201311","journal-title":"J Mol Diagn"},{"issue":"24","key":"4816_CR13","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12(24):7374\u20137379","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4816_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117\u2013125","journal-title":"Cancer Cell"},{"issue":"6","key":"4816_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112(6):831\u2013843","journal-title":"Cell"},{"issue":"3","key":"4816_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","volume":"16","author":"F Stagno","year":"2016","unstructured":"Stagno F, Stella S, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P (2016) Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Rev Anticancer Ther 16(3):273\u2013278","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"4816_CR17","doi-asserted-by":"publisher","first-page":"e1004578","DOI":"10.1371\/journal.pcbi.1004578","volume":"11","author":"S Lovera","year":"2015","unstructured":"Lovera S, Morando M, Pucheta-Martinez E, Martinez-Torrecuadrada JL, Saladino G, Gervasio FL (2015) Towards a molecular understanding of the link between imatinib resistance and kinase conformational dynamics. PLoS Comput Biol 11(11):e1004578","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"4816_CR18","doi-asserted-by":"publisher","first-page":"e0114828","DOI":"10.1371\/journal.pone.0114828","volume":"10","author":"S Vaidya","year":"2015","unstructured":"Vaidya S, Vundinti BR, Shanmukhaiah C, Chakrabarti P, Ghosh K (2015) Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS ONE 10(1):e0114828","journal-title":"PLoS ONE"},{"key":"4816_CR19","first-page":"1022","volume":"2","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K (2014) BCR-ABL point mutations and TKI treatment in CML patients. J Hematol Transf 2:1022\u20131033","journal-title":"J Hematol Transf"},{"issue":"1","key":"4816_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276\u2013283","journal-title":"Blood"},{"issue":"16","key":"4816_CR21","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O\u2019Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM et al (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26(16):6082\u20136093","journal-title":"Mol Cell Biol"},{"issue":"19","key":"4816_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz JL, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias. N Engl J Med 369(19):1783\u20131796","journal-title":"N Engl J Med"},{"issue":"3","key":"4816_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H et al (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26(3):428\u2013442","journal-title":"Cancer Cell"},{"issue":"6","key":"4816_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","volume":"127","author":"MW Deininger","year":"2016","unstructured":"Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, M\u00fcller MC, Li J, Parker WT et al (2016) Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 127(6):703\u2013712","journal-title":"Blood"},{"issue":"6","key":"4816_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"8","key":"4816_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648","journal-title":"Leukemia"},{"issue":"4","key":"4816_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3324\/haematol.2010.034173","volume":"96","author":"S Soverini","year":"2011","unstructured":"Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, Cimino G, Elia L, Lonetti A, Vignetti M, Paolini S (2011) Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 96(4):552\u2013557","journal-title":"Haematologica"},{"issue":"1","key":"4816_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/0971-6866.132758","volume":"20","author":"Z Iqbal","year":"2014","unstructured":"Iqbal Z (2014) A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology. Indian J Hum Genet 20(1):64","journal-title":"Indian J Hum Genet"},{"issue":"1","key":"4816_CR29","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","volume":"9","author":"C Chandrasekhar","year":"2019","unstructured":"Chandrasekhar C, Kumar PS, Sarma PV (2019) Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep 9(1):2412","journal-title":"Sci Rep"},{"key":"4816_CR30","first-page":"458716","volume":"2012","author":"SE Langabeer","year":"2012","unstructured":"Langabeer SE, McCarron SL, Kelly J, Krawczyk J, McPherson S, Perera K, Murphy PT (2012) Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol 2012:458716","journal-title":"Case Rep Hematol"},{"issue":"35","key":"4816_CR31","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041","journal-title":"J Clin Oncol"},{"key":"4816_CR32","unstructured":"Swerdlow SH (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. In: WHO classification of tumours 22008. WHO, Geneva, p 439"},{"issue":"9","key":"4816_CR33","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP et al (2002) High frequency of point mutations clustered within the adenosine triphosphate\u2013binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9):3472\u20133475","journal-title":"Blood"},{"issue":"12","key":"4816_CR34","first-page":"789","volume":"119","author":"K Lewandowski","year":"2009","unstructured":"Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G et al (2009) Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib. Polskie Archiwum Medycyny Wewn\u0119trznej 119(12):789\u2013794","journal-title":"Polskie Archiwum Medycyny Wewn\u0119trznej"},{"issue":"3","key":"4816_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2010.030999","volume":"96","author":"B Hanfstein","year":"2011","unstructured":"Hanfstein B, M\u00fcller MC, Kreil S, Ernst T, Schenk T, Lorentz C, Schwindel U, Leitner A, Hehlmann R, Hochhaus A et al (2011) Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96(3):360\u2013366","journal-title":"Haematologica"},{"issue":"5","key":"4816_CR36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, M\u00fcller MC, Ernst T, Rosti G, Porkka K et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208\u20131215","journal-title":"Blood"},{"key":"4816_CR37","doi-asserted-by":"crossref","unstructured":"Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M, ESMO Guidelines Working Group (2012) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl_7):vii72\u2013vii77","DOI":"10.1093\/annonc\/mds228"},{"issue":"1","key":"4816_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC et al (2011) Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1\u20131","journal-title":"Chem Biol Drug Des"},{"issue":"3","key":"4816_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F et al (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol 27(3):469\u2013471","journal-title":"J Clin Oncol"},{"issue":"7","key":"4816_CR40","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242\u20132249","journal-title":"Blood"},{"issue":"1","key":"4816_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14728214.2011.531698","volume":"16","author":"AC Burke","year":"2011","unstructured":"Burke AC, Swords RT, Kelly K, Giles FJ (2011) Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin Emerg Drugs 16(1):85\u2013103","journal-title":"Expert Opin Emerg Drugs"},{"key":"4816_CR42","unstructured":"Hughes TP, Branford S (2009) Monitoring disease response to tyrosine kinase inhibitor therapy in CML. In: ASH Education Program Book 2009(1), pp 477\u2013487"},{"issue":"4","key":"4816_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","volume":"47","author":"P Ros\u00e9e La","year":"2010","unstructured":"La Ros\u00e9e P, Deininger MW (2010) Resistance to imatinib: mutations and beyond. Semin Hematol 47(4):335\u2013343","journal-title":"Semin Hematol"},{"issue":"9","key":"4816_CR44","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9):2562\u20132569","journal-title":"J Clin Invest"},{"issue":"10","key":"4816_CR45","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I et al (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 114(10):2168\u20132171","journal-title":"Blood"},{"issue":"5","key":"4816_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H (2014) Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547\u2013556","journal-title":"Am J Hematol"},{"issue":"2","key":"4816_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MOH.0b013e3283366bcb","volume":"17","author":"M Osborn","year":"2010","unstructured":"Osborn M, Hughes T (2010) Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol 17(2):97\u2013103","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"4816_CR48","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11):4500\u20134505","journal-title":"Cancer Res"},{"issue":"4","key":"4816_CR49","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3892\/etm.2015.2707","volume":"10","author":"X Shen","year":"2015","unstructured":"Shen X, Zhang M, Shen Y, Shi W, Liu W, Wei W (2015) Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244\u00a0V mutations in a patient with chronic myelogenous leukemia: a case report. Exp Ther Med 10(4):1479\u20131482","journal-title":"Exp Ther Med"},{"issue":"6","key":"4816_CR50","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/leu.2008.65","volume":"22","author":"DW Sherbenou","year":"2008","unstructured":"Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW et al (2008) Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia 22(6):1184","journal-title":"Leukemia"},{"issue":"3","key":"4816_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.leukres.2007.04.018","volume":"32","author":"RP Curvo","year":"2008","unstructured":"Curvo RP, Zalcberg IR, Scholl V, Pires V, Moellmann-Coelho A, Moreira MA (2008) A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. Leuk Res 32(3):508\u2013510","journal-title":"Leuk Res"},{"issue":"11","key":"4816_CR52","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1158\/1535-7163.MCT-10-0595","volume":"9","author":"JB Gaillard","year":"2010","unstructured":"Gaillard JB, Arnould C, Bravo S, Donadio D, Exbrayat C, Jourdan E, Reboul D, Chiesa J, Lavabre-Bertrand T et al (2010) Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther 9(11):3083\u20133089","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4816_CR53","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1007\/s12032-011-0092-9","volume":"29","author":"N Meggyesi","year":"2012","unstructured":"Meggyesi N, Kalm\u00e1r L, Fekete S, Masszi T, Tordai A, Andrikovics H (2012) Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. Med Oncol 29(3):2136\u20132142","journal-title":"Med Oncol"},{"issue":"11","key":"4816_CR54","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3109\/10428194.2016.1157868","volume":"57","author":"N Patkar","year":"2016","unstructured":"Patkar N, Ghodke K, Joshi S, Chaudhary S, Mascerhenas R, Dusseja S, Kabre S et al (2016) Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leuk Lymphoma 57(11):2653\u20132660","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4816_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ajh.22272","volume":"87","author":"M Alikian","year":"2012","unstructured":"Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Rezvani K et al (2012) BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol 87(3):298\u2013304","journal-title":"Am J Hematol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-04816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:15:38Z","timestamp":1587683738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-04816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-04816-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}